214 related articles for article (PubMed ID: 19053884)
1. Tirapazamine: a novel agent targeting hypoxic tumor cells.
Reddy SB; Williamson SK
Expert Opin Investig Drugs; 2009 Jan; 18(1):77-87. PubMed ID: 19053884
[TBL] [Abstract][Full Text] [Related]
2. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
3. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA; Wilson WR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
[TBL] [Abstract][Full Text] [Related]
4. Is there a role for tirapazamine in the treatment of cervical cancer?
Ghatage P; Sabagh H
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1589-97. PubMed ID: 23033890
[TBL] [Abstract][Full Text] [Related]
5. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
Wouters BG; Wang LH; Brown JM
Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
[TBL] [Abstract][Full Text] [Related]
6. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
8. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
9. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown JM
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
[TBL] [Abstract][Full Text] [Related]
10. Tirapazamine-cisplatin: the synergy.
Gatzemeier U; Rodriguez G; Treat J; Miller V; von Roemeling R; Viallet J; Rey A
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):15-7. PubMed ID: 9647615
[TBL] [Abstract][Full Text] [Related]
11. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie MJ; Kovacs MS; Gabalski EC; Adam M; Le QT; Bloch DA; Pinto HA; Terris DJ; Brown JM
Neoplasia; 1999 Nov; 1(5):461-7. PubMed ID: 10933062
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
Brown JM
Mol Med Today; 2000 Apr; 6(4):157-62. PubMed ID: 10740254
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
15. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice.
Durand RE; Olive PL
Radiat Oncol Investig; 1997; 5(5):213-9. PubMed ID: 9372543
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
17. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
Masunaga S; Ono K; Nishimura Y; Kanamori S; Saga T; Suzuki M; Kinashi Y; Takagaki M; Kasai S; Nagasawa H; Uto Y; Hori H
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):799-807. PubMed ID: 10837967
[TBL] [Abstract][Full Text] [Related]
19. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
20. Bioreductive drugs: from concept to clinic.
McKeown SR; Cowen RL; Williams KJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
